Long-term treatment with nipradilol, a nitric oxide–releasing β-adrenergic blocker, enhances postischemic recovery and limits infarct size

2002 ◽  
Vol 73 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Yoshihiro Suematsu ◽  
Toshiya Ohtsuka ◽  
Hitoshi Horimoto ◽  
Katsuhide Maeda ◽  
Yasunari Nakai ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Infarct Size ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Adrenergic Blocker ◽  
Nitric Oxide Releasing ◽  
Postischemic Recovery

scholarly journals Long-Term Treatment of Anterior Pituitary Cells with Nitric Oxide Induces Programmed Cell Death

Endocrinology ◽  
2004 ◽  
Vol 145 (4) ◽  
pp. 2064-2070 ◽  
Author(s):  
Miguel Omar Velardez ◽  
Ariel Hernán Poliandri ◽  
Jimena Paula Cabilla ◽  
Cristian Carlos Armando Bodo ◽  
Leticia Inés Machiavelli ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Anterior Pituitary ◽  
Term Treatment ◽  
Pituitary Cells ◽  
Anterior Pituitary Cells ◽  
Long Term Treatment

Long-Term Treatment of Essential Hypertension with Nadolol and Hydrochlorothiazide: A Two-Year Follow-Up

1982 ◽  
Vol 10 (2) ◽  
pp. 87-91 ◽  
Author(s):  
M M El-Mehairy ◽  
A Shaker ◽  
M Ramadan ◽  
S Hamza ◽  
S S Tadros
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Combined Therapy ◽  
Term Treatment ◽  
Once Daily ◽  
Supine Blood Pressure ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Adrenergic Blocker

After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.

Induction of apoptosis in T lymphoma cells by long-term treatment with thyroxine involves PKCζ nitration by nitric oxide synthase

APOPTOSIS ◽  
2013 ◽  
Vol 18 (11) ◽  
pp. 1376-1390 ◽  
Author(s):  
M. L. Barreiro Arcos ◽  
H. A. Sterle ◽  
C. Vercelli ◽  
E. Valli ◽  
M. F. Cayrol ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Term Treatment ◽  
Lymphoma Cells ◽  
Long Term Treatment ◽  
T Lymphoma Cells ◽  
Induction Of Apoptosis ◽  
T Lymphoma ◽  
Oxide Synthase
Sign in / Sign up

Export Citation Format

Share Document